A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms FEATURE
  • Sponsors Novartis
  • Most Recent Events

    • 10 Apr 2017 Results (n=1709) of a pooled analysis from FIXTURE, FEATURE, ERASURE and JUNCTURE studies assessing the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients, published in the Advances in Therapy.
    • 28 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 16 Feb 2017 This trial has been completed in Germany (end date: 24 Oct 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top